Year-over-year earnings per share growth for the last twelve months: Werewolf Therapeutics (HOWL)

Werewolf Therapeutics, Inc. (HOWL) - corporate logo

Werewolf Therapeutics focuses on the targeted delivery of immunostimulants into tumors to minimize side effects. This quarterly EPS trend captures the market reaction, where the value of 118.80 corresponds to the current metric. Financial stability currently depends on external research funding, while the company's impeccable scientific reputation in oncology maintains a high level of investor confidence.

Werewolf Therapeutics Inc. (HOWL) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for Werewolf Therapeutics (HOWL)

- share price and expert price forecast:
Stock Price werewolftx.com|HOWL - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Werewolf|HOWL - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Werewolf Therapeutics|HOWL - Company Net Assets|Market Cap to Net Assets Ratio werewolftx.com|HOWL - Company Total Assets
- debt and liquidity details:
Debt to Equity Werewolf Therapeutics|HOWL - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity werewolftx.com|HOWL - Company Cumulative Debt|Debt to Book Value Werewolf|HOWL - Long-Term Indebtedness|Company Current Liabilities Werewolf Therapeutics|Quick Ratio werewolftx.com
- earnings and market multiples details:
HOWL - Final Profit|Projected Future Earnings Werewolf Therapeutics|HOWL - Market Cap to Earnings|Future Price to Earnings werewolftx.com|HOWL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Werewolf|HOWL - Operating profit EBITDA|Earnings per share for the last twelve months Werewolf Therapeutics|HOWL - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months werewolftx.com|HOWL - Earnings per share growth rate in current year|Expected earnings per share growth for next year Werewolf Therapeutics
Comprehensive company analysis:Werewolf Therapeutics Inc., HOWL
Manufactured product of werewolftx.com

Unique patents and stringent FDA oversight create colossal barriers to entry for Werewolf Therapeutics (HOWL), driving high R&D costs. The growth rate of quarterly earnings per share measures net income dynamics, smoothing the gaps between reports to assess current business momentum, which allows investors to promptly identify margin compression risks or confirm the asset's fundamental stability.

Competitors of Werewolf Therapeutics

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Janux Pharma|Year-over-year net earnings per share growth for the last 12 months Arcus Corp (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc. (ZYME)|Year-over-year net earnings per share growth for the last 12 months tangotx.com TNGX|Iovance Biotherapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics NV IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (Compass Therapeutics Corp) - Year-over-year earnings per share growth for the last 12 months|Replimune Group, Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months lyell.com (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months CGEN (Compugen Ltd.)|Year-over-year earnings per share growth rate for the last twelve months IOBT|Quarterly EPS earnings growth STRO (Sutro Biopharma, Inc.)|Year-over-year earnings per one share growth for the last 12 months INKT|Immix - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months alxoncology.com|Cue Biopharma (CUE) - Year-over-year earnings per share growth for the last twelve months|PDS Biotechnology Corporation - Year-over-year earnings per one share growth for the last 12 months|SONN (Sonnet BioTherapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIABiotech.com|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Corp - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics Inc (LPTX) - Earnings per share growth in annualized terms for the last twelve months|INTS: Year-over-year net earnings per share growth for the last 12 months|Sensei Biotherapeutics (SNSE) - Year-over-year net earnings per share growth for the last 12 months|TOVX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Gritstone bio (GRTS)|Year-over-year earnings per share growth for the last twelve months Kineta Bio|NEXI: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth TSBX|VCNX - Earnings per share growth in annualized terms for the last twelve months|Harpoon Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months